NCT02651285 is a Phase 4 clinical trial of G-CSF medium in Infertility, sponsored by Centre for Endocrinology and Reproductive Medicine, Italy.

Who is sponsoring NCT02651285?

NCT02651285 is sponsored by Centre for Endocrinology and Reproductive Medicine, Italy.

What drugs are being tested in NCT02651285?

Interventions in NCT02651285: G-CSF medium, Control.

What condition does NCT02651285 study?

NCT02651285 studies Infertility, Embryo Development, IVF.

Is NCT02651285 still recruiting?

NCT02651285 is currently status unknown. Last updated 7 January 2016.

Last reviewed 2016-01-07 · How we verify

NCT02651285

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

G-CSF Supplemented Medium for IVF Embryo Culture in Patients Undergoing IVF

Status unknown Phase 4 Last updated 7 January 2016

What this trial tests

Phase 4 trial testing G-CSF medium in Infertility in 180 participants. Status unknown.

Timeline

1 January 2016

Primary endpoint
1 December 2016

1 March 2017

Quick facts

Lead sponsor	Centre for Endocrinology and Reproductive Medicine, Italy
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Enrollment	180
Start date	1 January 2016
Primary completion	1 December 2016
Estimated completion	1 March 2017
Sites	1 location across Italy

Drugs / interventions tested

G-CSF medium
Control

Conditions studied

Infertility — all drugs for Infertility →
Embryo Development — all drugs for Embryo Development →
IVF — all drugs for IVF →

Sponsor

Centre for Endocrinology and Reproductive Medicine, Italy — full company profile →

Who can join

Adults 20 to 38, female only, with Infertility or Embryo Development. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

pregnancy rate
Time frame: 12 months
The number of patients become pregnant after IVF where G-CSF medium is used divided for the number of patients treated
implantation rate
Time frame: 12 months
The number of embryos implanted after IVF where G-CSF medium is used divided for the number of embryos transferred

Sponsor's own description

The purpose of this study is to determine whether in Assisted Reproductive Technologies the use of culture medium supplemented with G-CSF, a growth factor working on stem cells, may improve the embryo implantation and pregnancy rate in infertile patients undergoing IVF cycles.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

GM-CSF (granulocyte macrophage colony-stimulating factor) supplementation in culture media for women undergoing assisted reproduction.
Armstrong S, MacKenzie J, Woodward B, Pacey A, et al · · 2020 · cited 10× · PMID 32672358 · DOI 10.1002/14651858.cd013497.pub2

Verify or expand the search:

Other recruiting trials for Infertility

Currently open trials in the same condition.

NCT07074015 — IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Speci · NA · recruiting
NCT07358468 — Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study · recruiting
NCT07340827 — A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH · Phase 3 · recruiting
NCT07369362 — To Investigate if the Harvester® Improves Sperm Motility and Blastocyst Utilization (the Percent of Fertilized Eggs That · NA · active not recruiting
NCT07153367 — Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauter · Phase 2 · recruiting

Other Centre for Endocrinology and Reproductive Medicine, Italy trials

Trials by the same sponsor.

NCT06641440 — Treatment With Prednisone of Women With RPL or RIF Positive to Antithyroid Antibodies and Embryotoxicity Test · Phase 4 · completed
NCT03421639 — Aromatase Plus GnRH Analogue Versus GnRH Analog Alone in Adenomyosis · Phase 4 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02651285 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre for Endocrinology and Reproductive Medicine, Italy
Last refreshed: 7 January 2016

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02651285.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing